AI Medical Service Inc.
- Industry
- Medical Technology
- Founded Year
- 2017
- Headquarters
- Hareza Tower 11F, 1-18-1 Higashi-ikebukuro, Toshima-ku, Tokyo 170-0013, Japan
- Employee Count
- 100
Key People
-
Tomohiro Tada - CEO and Founder
Email: pr@ai-ms.com
- Kazugen Aoyama - Director & CTO
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: Led by experienced professionals with a strong background in medical technology.
The CEO, Dr. Tomohiro Tada, has a robust background in gastroenterology and medical innovation, contributing significantly to the company's strategic direction and product development.
- Clinical Need
-
Aspect: Very Strong
Summary: Addresses a critical need for early detection of gastrointestinal cancers.
Gastric cancer is a leading cause of cancer-related deaths globally. AI Medical Service's AI-driven endoscopic diagnostics aim to enhance early detection rates, potentially reducing mortality and improving patient outcomes.
- Competition
-
Aspect: Somewhat crowded
Summary: Operates in a competitive market with several players in AI diagnostics.
The medical AI diagnostics field is growing, with various companies developing similar technologies. AI Medical Service must leverage its unique strengths to stand out in this competitive landscape.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing reliable AI diagnostics presents moderate technical challenges.
Creating AI systems that can accurately detect and diagnose gastrointestinal cancers involves complex algorithm development and extensive training data, posing moderate technical challenges.
- Patent
-
Aspect: Applied
Summary: Has applied for patents to protect its technology.
Securing patents for its AI technology can strengthen AI Medical Service's market position and protect its innovations from competitors.
- Financing
-
Aspect: Well-funded
Summary: Successfully raised significant funding, including a Series C round.
The company's ability to secure substantial funding, notably from prominent investors like SoftBank Vision Fund, indicates investor confidence and provides resources for growth and product development.
- Regulatory
-
Aspect: 510k/PMA
Summary: Pursuing regulatory approvals in multiple regions.
AI Medical Service has obtained regulatory approvals in Japan and Singapore and is actively seeking approvals in other markets, demonstrating a proactive approach to compliance and market expansion.
Opportunity Rollup
- Odds of Success
- 4.2
- Peak Market Share
- 5.8
- Segment CAGR
- 10.7%
- Market Segment
- Diagnostic Imaging
- Market Sub Segment
- Endoscopy Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.29 |
| 2 | 0.87 |
| 3 | 2.03 |
| 4 | 4.06 |
| 5 | 5.80 |
Key Takeaway
AI Medical Service Inc. is well-positioned to address a critical clinical need with its AI-driven endoscopic diagnostics, supported by strong leadership, substantial funding, and strategic partnerships, despite facing a competitive market and technical challenges.